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Abstract 
BACKGROUND: Huntington’s disease is marked by progressive neuroanatomical changes, assumed 
to underlie the development of the disease’s characteristic symptoms. Previous work has 
demonstrated longitudinal macrostructural white-matter atrophy, with some evidence of 
microstructural change focused in the corpus callosum.  
OBJECTIVE: To more accurately characterise longitudinal patterns, we examined white matter 
microstructural change using Diffusion Tensor Imaging (DTI) data from three timepoints over a 15 
month period.  
METHODS: In 48 early-stage HD patients and 36 controls from the multi-site PADDINGTON project, 
diffusion tensor imaging (DTI) was employed to measure changes in fractional anisotropy (FA) and 
axial (AD) and radial diffusivity (RD) in 24 white matter regions-of-interest (ROIs). 
RESULTS: Cross-sectional analysis indicated widespread baseline group differences, with significantly 
decreased FA and increased AD and RD found in HD patients across multiple ROIs. Longitudinal rates 
of change differed between HD patients and controls in the genu and body of corpus callosum, 
corona radiata and anterior limb of internal capsule. Change in RD in the body of the corpus 
callosum was associated with baseline disease burden, but other clinical associations were not 
significant. 
CONCLUSIONS: We detected subtle longitudinal white matter changes in early HD patients. 
Progressive white matter abnormalities in HD may not be uniform throughout the brain, with some 
areas remaining static in the early symptomatic phase. Longer assessment periods across disease 
stages will help map this progressive trajectory. 
Keywords: Huntington’s disease, Diffusion Tensor Imaging, Longitudinal, Symptomatic  
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Introduction 
Huntington’s disease (HD) causes progressive neurodegeneration, leading to debilitating motor, 
cognitive and psychiatric symptoms. Despite identification of the gene responsible for HD [1] and 
subsequent years of concerted clinical and research efforts, the search for disease-modifying 
treatments is still in its infancy. 
Studying HD in vivo using magnetic resonance imaging (MRI) is a powerful approach for improving 
our understanding of the disease’s progressive nature. Used to elucidate aspects of the neural 
pathogenesis of HD in the striatum, studies using volumetric approaches have also shown that HD 
pathology extends to macrostructural abnormalities within cortical and white matter regions [2-6]. 
By employing diffusion tensor imaging (DTI), we can similarly investigate microstructural changes in 
white matter with several studies already having identified abnormalities in manifest HD gene-
carriers [7-11], pre-manifest HD (preHD) gene carriers [12-17] and across multiple disease stages [5, 
18-30].  
Cross-sectional DTI studies which have included both preHD and early-HD gene-carriers have 
attempted to characterise disease progression, but this is better achieved by conducting longitudinal 
analyses which can map individual patterns of change. There is strong evidence of progressive 
macrostructural white matter degeneration [31-39] and current evidence suggests that longitudinal 
change in caudate nucleus volume is a particularly promising candidate neuroimaging biomarker for 
future clinical trials [36]. If the microstructural properties captured by DTI are more sensitive to the 
cellular processes underlying neurodegeneration [40], DTI may potentially be a better index of HD 
progression than macrostructural volumetric methods. Thus, further longitudinal DTI analysis of 
white matter in HD is warranted. However, only a limited number of studies have examined DTI in 
HD longitudinally (see Rees et al., for review [41]) and these have generally either been restricted to 
striatal grey matter regions [42, 43], or limited in sample size and scope. For example, white matter 
change was investigated in a small combined group (N = 7) of early HD and preHD gene carriers 
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using whole-brain tract-based spatial statistics (TBSS) [44, 45]. This preliminary research identified 
longitudinal decreases in fractional anisotropy (FA) and axial diffusivity (AD) after one year in the HD 
patients when compared to a matched control group. Conversely, Sritharan and colleagues [46] 
were unable to detect similar changes over the same interval, using a region-of-interest (ROI) 
approach in a larger sample of 18 HD patients and 17 controls. However, this analysis only examined 
mean diffusivity (MD) of the corpus callosum. A recent study has investigated longitudinal change 
over 18 months using data from two timepoints in a larger group of preHD and early HD gene-
carriers [29]. Again, using TBSS, they have shown that when compared to both preHD and control 
groups, early HD gene-carriers have reduced FA in the genu, body and splenium of the corpus 
callosum and mid cingulum and that callosal FA levels are predicted by the Unified Huntington’s 
Disease Rating Scale Total Motor Score (UHDRS-TMS)[47]. Furthermore, there was evidence of 
increased radial diffusivity (RD) in the corpus callosum, cingulum, internal capsule and striatal 
projections when compared to the premanifest, but not the control group.  
Another recent study applying histogram analysis to DTI data over 24 months using data from two 
timepoints, assessed microstructural properties of whole-brain gray matter, white matter and the 
striatum in different stages of HD [30]. In that study evidence was found for alterations in cross-
sectional diffusion profiles between early manifest HD and preHD subjects compared to healthy 
controls, without evidence for longitudinal differences in the degree of diffusivity change between 
the groups. Investigating the structural connectome using the same dataset by applying graph 
theoretical analysis, Odish and colleagues revealed longitudinal differences between early manifest 
HD, preHD subjects and controls in various network measures[48]. These results further emphasise 
the importance of exploring different analytical approached to study the biomarker potential of 
diffusion MRI. 
The aim of the current study was to investigate progressive alterations in white matter 
microstructure during the early stages of symptomatic HD using multi-site DTI data combined with 
an ROI approach. To more clearly characterise longitudinal change, we used three timepoints over a 
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15 month interval to track the subtle, non-linear changes in progression across this period. We 
focussed on FA as a measure of the direction of diffusivity, in addition to both AD and RD which 
respectively index water movement parallel and perpendicular to the main fibre. We investigated 
white matter changes with respect to genetic factors (i.e. CAG repeat length) and disease burden, as 
these markers of HD show associations with cross-sectional white matter abnormalities [8, 23, 24] 
and in using the ROI approach, this analysis was designed to highlight specific brain regions for 
future evaluation as DTI-derived biomarkers for potential therapeutic studies.  
Materials and Methods 
Participants 
61 HD patients and 40 control participants were recruited as part of the PADDINGTON study [11] 
across four study sites (Leiden, Netherlands; London, UK; Paris, France; Ulm, Germany). Participants 
attended three separate study visits, with an initial baseline and subsequent 6-month and 15-month 
follow-ups. Due to a combination of participant dropout, missing data and quality control failure, 17 
participants (13 HD patients, 4 controls) did not have complete diffusion MRI datasets for all three 
visits (two missing 6-month assessment; 15 missing 15-month); hence 84 participants (48 HD 
patients and 36 controls – see Table 1) were included in the final analysis. These exclusions were 
necessary as the longitudinal image registration scheme outlined below cannot account for missing 
image data. Excluded HD patients had marginally higher disease burden and Total Motor Score 
(TMS) and lower Total Functional Capacity (TFC) at baseline but overall the demographic differences 
were minimal (see Supplementary Table 1).  
In addition to MRI data, behavioural, cognitive and clinical assessments were performed at each 
visit. All patients had received a diagnosis of manifest HD, were at disease stage I [49] and had a 
baseline UHDRS TFC score between 11-13. One patient had a TFC score of 9 and was classified as 
disease stage II (this score remained stable across all study visits). CAG repeat length was assessed to 
confirm diagnosis and all patients had between 39-54 repeats. Control participants were spouses, 
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partners or gene-negative siblings of the HD patients. Inclusion criteria were: 18–65 years of age, no 
diagnosis of psychiatric or other neurological disorders, not currently taking part in other 
pharmacological research and no contraindication to MRI scanning. The respective local ethical 
committees for each study site approved the study and written informed consent was obtained from 
each participant. 
Data acquisition 
3T MRI Diffusion-weighted T1 structural and DTI images were acquired at all sites.  
T1 Imaging parameters: For the Siemens Tim Trio and Verio scanners (London and Paris respectively) 
the T1 MP-RAGE scans were acquired with the following parameters: TR = 2200ms, TE = 2.2ms, flip 
angle = 10°, FOV = 28cm, matrix size = 256x256, yielding 208 sagittal slices with a slice thickness of 
1.0 mm with no inter-slice gap. For the Siemens Allegra (Ulm), parameters were as above except TE 
= 2.81ms, flip angle = 9° and a slice thickness of 1.1 mm For the Philips Achieva scanner (Leiden) T1-
weighted magnetisation-prepared rapid gradient echo (MP-RAGE) scans were acquired with the 
following parameters; TR = 7.7ms, TE = 3.5ms, flip angle = 8°, FOV = 24cm, matrix size = 224x224, 
yielding 164 sagittal slices to cover the entire brain with a slice thickness of 1.0 mm with no inter-
slice gap. 
DTI Imaging Parameters: For the Siemens Tim Trio (London) DTI data were acquired using an EPI 
sequence with the following parameters: 65 axial slices of 2 mm thickness, with no inter-slice gaps, 
acquisition matrix = 96 x 128, in-plane resolution of 2 mm2, resulting in isotropic voxels (TR = 7600 
ms, TE = 84 ms). For the Siemens Verio (Paris) DTI data were acquired using an EPI sequence with 
the following parameters; 75 axial slices of 2 mm thickness, with no inter-slice gaps, acquisition 
matrix = 128 x 128, in-plane resolution of 2 mm2, resulting in isotropic voxels (TR = 13100 ms, TE = 86 
ms). For both, data were acquired in 42 different encoding directions with b = 1000 s/mm2, along 
with 7 b = 0 images. For the Siemens Allegra (Ulm), each data volume consisted of 52 axial slices of 
2.2 mm thickness, with no inter-slice gaps, acquisition matrix = 96 x 128, in-plane resolution of 2.2 
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mm2, resulting in isotropic voxels (TR = 7600 ms, TE = 85 ms). Diffusion data were acquired in 47 
different encoding directions with b = 1000 s/mm2, along with three b = 0 images. For the Philips 
Achieva scanner (Leiden) DTI data were acquired using the following parameters; 55 axial slices of 2 
mm thickness, with no inter-slice gaps, acquisition matrix = 112 x 112, in-plane resolution of 2 mm2, 
resulting in isotropic voxels (TR = 8062 ms, TE = 56 ms). Diffusion data were acquired in 42 different 
encoding directions with b = 1000 s/mm2, along with one b = 0 image. 
For further details on acquisition parameters and pooling of multi-site site data see our previous 
work on this sample [11, 50]. Visual quality control was performed to check for acquisition protocol 
compliance, artefacts and head positioning. Rescans were requested for four participants and scans 
were excluded due to failure to meet the required quality criteria, leaving 84 participants for the 
analysis. All image processing and analysis was performed blinded to participant diagnosis. All site 
effects were modelled within the analysis. 
Data pre-processing 
Diffusion-weighted images were initially registered to the corresponding b0 reference image to 
correct for motion and eddy current distortions, with updates applied to the gradient scheme 
accordingly. Subsequently, a non-linear least-squares method was used to fit the tensor at each 
voxel, using Camino [51]. Tensor-based registration was then performed using DTI-TK (http://dti-
tk.sourceforge.net) [52]. This offers improvements over conventional scalar-based registration as it 
incorporates information from local fibre orientations and has been shown to improve the sensitivity 
of DTI metrics to microstructural group differences [53, 54]  and the performance of study-specific 
atlas generation [55]. We employed a well-established specific longitudinal registration procedure, 
which registers average within-subject templates to a study-specific group template; this avoids 
biases caused by asymmetric image registration or imbalanced application of interpolation schemes 
[56] (see Figure 1). In short, for every participant, tensor images for each visit were co-registered 
together to form a ‘bootstrap’ template, then each image was non-linearly registered to the 
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template using an iterative approach. The resulting affine and non-linear registrations were then 
combined so that the input images could be mapped to subject-template space in one interpolation 
step [57]. A group template was then created using this same iterative affine and non-linear 
procedure; with participant average images as input. Again, transformations were combined to take 
within-participant template images to group template space with one interpolation. This resulted in 
all participants’ tensor images being spatially normalised to a study-specific group template, from 
which individual subject maps for FA, AD and RD could be generated for further processing and 
statistical analysis. 
Atlas-based ROI analysis 
To define our ROIs, we used the 2mm3 ICBM-DTI-81 atlas [58] employed within FSL software. Based 
on our previous work [59], the number of regions was reduced from 48 to 24 to include only those 
with high test-retest reliability for FA, AD and RD (i.e. intraclass correlation coefficient > 0.8) (Tables 
2 and 3). It should be noted that the current sample includes the subsample reported in [59]. 
However, the analysis in that study used sequentially acquired data from a single visit, not multiple 
timepoints, and therefore presents no confound when using that data to inform the selection of 
ROIs for the present study. The DTI-81 atlas was registered to the group FA template using the Nifty-
Toolkit (http://sourceforge.net/projects/niftyreg) components Aladin, for affine registration [60] and 
F3D, for non-linear refinement [61]. The computed transformation was then used to warp the label 
files to match the group FA template. The group FA template was thresholded at FA > 0.2 and below-
threshold voxels removed from DTI-81 label images in group-template space. The mean value of 
each metric (FA, AD and RD) was then calculated across each ROI for each participant at each visit. 
Statistical analysis 
All analysis was conducted in STATA version 13. The repeated measures of each ROI/metric 
combination were separately analysed using generalised least squares regression models, with 
outcome variance (and correlations between pairs of measures) allowed to differ both by disease 
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group and by visit. The models included a group factor (HD patient or Control), time from baseline 
(in days) and a quadratic term that modelled non-linear change over the three visits. Also, baseline 
covariates of age, sex and study site were included. Interaction terms between time (both linear and 
quadratic) and all other variables were included. The primary measures of interest were group 
differences at baseline and in change over 15 months. Due to the large number of ROIs and ensuing 
increased risk of false positives, a correction for multiple testing was carried out using a procedure 
to control the False Discovery Rate (FDR) [62] at 5%. It was considered appropriate to do this for 
each metric separately, thus corrections were based on analysing 24 ROIs. Due to a priori concern of 
between-site differences, two interaction terms were tested using the same multiple comparison 
procedure as above: baseline interaction between group and study site, three-way site by group by 
time (both linear and quadratic) interaction. If the three-way interaction was significant, then both 
the baseline group differences and the between-group difference in 15-month change were 
reported by site. If only the baseline interaction between site and group was significant, this was 
retained in the model and a single between-group difference in 15-month change reported (non-
significant three-way interactions were removed for clarity). If neither interaction was statistically 
significant they were both removed from the model. FDR correction for the primary measures of 
interest was conducted after removal of any measures that needed to be reported as site-specific.  
Clinical associations 
Longitudinal imaging measures were tested for associations with baseline CAG and disease burden 
score DBS) in the HD participant group only. This was restricted to those measures identified as 
having shown significant between-group differences in 15-month change. For simplicity, a linear 
regression was used to model 15-month change with an adjustment for the baseline diffusion value. 
Additional adjustments were also made for age, sex and study site. Again, interaction between 
group and site was allowed for, and if significant, site-specific associations were presented. If not, 
the interaction was removed from the model. As above, p-values were adjusted using FDR 
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correction at 5%, this time based on the number of measures carried through to the secondary 
analysis.  
Results 
Baseline comparison of early HD patients and controls 
To provide context for understanding longitudinal changes, we investigated cross-sectional 
differences between early HD patients and controls at baseline. All 24 regions showed statistically 
significant group differences (corrected for multiple comparisons) for at least one metric, with the 
HD group demonstrating either decreases in FA or increases in AD or RD when compared with 
controls (Table 2). Regions where all three DTI metrics showed significant differences were the three 
subdivisions of the corpus callosum (genu, body and splenium), the left external capsule and left 
bilateral sagittal stratum. There were no regions where increased FA was evident in the HD group, 
nor where decreased AD or RD was found.  
Comparison of longitudinal changes in early HD patients and controls 
DTI metrics showed significant differences in rates of change between early HD patients and controls 
in nine regions (see Figure 2 and Table 3). The genu and body of the corpus callosum showed 
reduced FA and increased RD, with increased AD in the genu only. There was increased RD and AD in 
the left anterior corona radiata; and increases in AD were also evident in both the right superior 
corona radiate and anterior limb of internal capsule. All differences were significant following 
multiple correction. Four metrics showed evidence of interaction between group differences in 15-
month change and site (see Supplementary Table 2).  
If between-group differences were driven by disease, we would expect to see a relatively flat 
trajectory of DTI measures over time for the control group, coupled with a deterioration in HD 
subjects to reflect disease progression. As an informal check, we plotted the model-estimated 
trajectories of diffusivity measures throughout the study period in controls and HD groups 
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separately. Fitted values are shown for hypothetical participants age 50, with a 50/50 male-female 
split and a 25% contribution from each site (Figure 3). Examination of the example trajectories 
highlighted FA in the genu of corpus callosum, AD in the anterior limb of internal capsule and right 
superior corona radiata and RD in the left anterior corona radiata as matching this pattern. The 
longitudinal trajectory in other regions indicated a possible regression to the mean in controls 
influencing the detected group differences in rates of change over time. 
Clinical associations with longitudinal neuroimaging measures 
The nine measures that reached statistical significance for longitudinal change (Table 3) were 
examined for associations between 15-month change and baseline CAG and disease burden in the 
HD subjects. Estimates and 95% confidence intervals are displayed in Table 4. After correction for 
multiple comparisons, only RD in the body of the corpus callosum showed a significant association 
with disease burden, with other measures showing directionally consistent but only borderline 
statistically significant results. After adjustment for a FDR of 5% there was no evidence that the 
associations differed between study sites.  
Discussion 
Early-stage HD gene-carriers show progressive changes in white matter microstructure in a number 
of key tracts when compared with healthy, age-matched controls. Using multi-site data, we have 
demonstrated widespread cross-sectional differences in diffusivity at baseline between controls and 
early stage HD, with longitudinal change in a number of key tracts including the genu and body of 
corpus callosum, left anterior corona radiata, right superior corona radiata and right anterior limb of 
internal capsule. 
Our cross-sectional findings at baseline concur with previous work using the current cohort [11] and 
much of the previous DTI research examining white matter in early-stage HD, which  demonstrated 
abnormalities in the corpus callosum [18, 19, 24, 27, 63] and more widely throughout the brain [5, 7-
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10, 20-23, 26, 28, 30]. We have also shown longitudinal change in the corpus callosum, corona 
radiate, and right anterior internal capsule across a series of DTI metrics, which supports evidence 
from previous longitudinal studies [29, 45]. Weaver et al., for example, identified FA decreases at 
follow-up in the corpus callosum, internal capsule and corona radiate. Most significantly, however, 
the recent longitudinal study by Poudel et al. demonstrated that the most robust white matter 
changes in manifest HD occur within the corpus callosum [29]. Both the current study and that of 
Poudel have shown that in early HD there are FA increases and RD decreases in the corpus callosum 
when compared with controls. Although this previous study used only two timepoints, incorporating 
a longer period of change, and a whole-brain rather than an a priori hypothesis driven method, 
findings are still highly consistent regarding the corpus callosum. These three studies highlight a 
consistent disturbance within the corpus callosum above all other white matter tracts. This is 
compatible with the aforementioned extant evidence at the cross-sectional level which robustly 
demonstrates white matter abnormalities within the corpus callosum. Despite concordance 
concerning measures of RD and FA, there is far greater inconsistency in terms of AD measures.  We 
saw increased AD not only in the corpus callosum, but also the anterior and superior corona radiate 
and the anterior internal capsule. Weaver, however, reported decreased AD in a small set of voxels 
[45], these differences likely due to low statistical power and variability in terms of disease 
progression; while Poudel et al. did not show any significant differences in AD at all [29]. Cross-
sectional studies of early HD patients have previously shown increases in AD compared with controls 
[7, 11, 18, 27, 30] and there is evidence that the negative correlation between AD and RD acts as an 
independent predictor of HD disease progression (see unpublished data – Mike O). However, given 
the limited number of studies examining longitudinal change in white matter, further replication of 
our findings would be required to confirm the increases in AD in early HD gene-carriers. It is 
important to note that some longitudinal differences may potentially be driven by a regression to 
the mean in controls, rather than being explicitly disease-related. Nevertheless, some regions do 
appear to show a consistent trajectory of change in early HD patients, while those of the controls 
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remaining static (e.g. genu FA, right anterior limb of internal capsule AD, right superior corona 
radiata AD, left anterior corona radiata RD).  
Inferring specific biological processes underlying alterations in DTI metrics can be contentious [64]. 
Animal studies combining DTI and histology to model white matter damage [65, 66] and HD 
specifically [67] have indicated that differing pathological processes may underlie AD and RD 
measurements. Under this assumption, RD increases reflect demyelination [68], while changes in AD 
are more complex and time-dependent. Decreases in AD are thought to occur in response to acute 
axonal damage and inflammation [69]; conversely AD increases reflect expanded extra-cellular 
spaces resulting from Wallerian degeneration and other more gross atrophic processes [70, 71]. 
However, we would caution against the over-interpretation of instances where, for example, AD was 
significant and RD was not. Cellular modifications caused by HD pathology undoubtedly affect white 
matter, but the mechanisms underlying this are unclear. Elements of intrinsic axonal degeneration, 
altered fibre coherence or configuration due to inflammation, decreased axonal density or 
demyelination all occur during the progression of HD and current DTI methods lack such aetiological 
specificity. More recent developments in diffusion MRI [72-76], may be more aetiologically-
informative regarding microstructural white matter changes occurring during HD progression.  
Analysis of clinical associations found a relationship between DBS and change in RD in the body of 
corpus callosum, with greater disease burden at baseline related to greater increases in RD over 15 
months during the early stages of manifest HD. Again, it is the corpus callosum that is most 
significantly targeted and, notwithstanding the aforementioned caveats, this may reflect on-going 
demyelination in the corpus callosum of the more severe patients, in line with previous evidence for 
corpus callosum abnormalities in early HD [18, 19, 24, 27, 63]. The number of associations between 
DTI metrics and clinical measures that did not reach statistical significance was however, 
unexpectedly high. Poudel et al also found that when correlating FA with a series of clinical 
measures, only UHDRS-TMS scores were significant predictors of white matter microstructural 
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changes [29], illustrating the potential difficulty in demonstrating clear relationships between clinical 
measures and longitudinal neuroimaging metrics. While this has been achieved using robust 
volumetric methods [36-38], issues regarding signal-to-noise ratio, reliability and validity hinder both 
DTI and many clinical measures and detecting associations may be better achieved by adopting 
novel diffusion-imaging techniques or by combining multiple imaging modalities with clinical data in 
a multivariate framework. 
Combining data from multiple scanners can present limitations, however our previous work has 
demonstrated that the cross-site pooling of data does not introduce bias in DTI analyses [50]. 
Furthermore, longitudinal within-participant change measures were not confounded by scanner 
differences. Our study did not model any potentially confounding effects of medication on white 
matter metrics. However, given the considerable heterogeneity in medication usage among the 
participants, it would not have been possible to test medication effect systematically.  
In conclusion, patients in the early stages of clinically-manifest HD show robust abnormalities in 
white matter structure throughout the brain, most robustly in the corpus callosum. Moreover, some 
of those regions appear to be undergoing microstructural degeneration as the disease progresses 
during the early diagnosed stages, with some evidence for a relationship between disease burden 
and structure of the corpus callosum. Despite these findings, our results demonstrate the difficulties 
in mapping effects of clinical variables onto a dynamically and heterogeneous pattern of brain 
changes that take place during early HD. Novel diffusion imaging methods which provide more 
information regarding the biological underpinnings of changes in white matter microstructure are 
required to further understand the heterogeneity of such alterations within HD. Furthermore, the 
use of multivariate modelling, which incorporates both imaging and clinical data, will also help to 
understand how white matter changes are related to clinical symptoms. 
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Tables 
Table 1. HD patient and control characteristics 
Baseline characteristics Controls Early HD patients 
N 36  48  
Age (Years) [Mean (SD) Range] 51.82 (8.75) 28.98 - 66.64 48.94 (9.38) 26.77 - 67.29 
Sex (Female/Male N (%)) 20 / 16 (55.6%) / (44.4%) 29 / 19 (60.4%) / (39.6%) 
Education Level (ISCED) [Mean (SD) 
Range] 
3.97 (1.23) 2 - 6 3.42 (1.27) 2 - 6 
Baseline-15 month interval (Days) 
[Mean (SD) Range] 
439.75 (32.27) 342-491 452.52 (43.44) 370-565 
Centre      
Leiden N (%)  9 (25%) 11 (22.92%) 
London N (%)  10 (27.78%) 13 (27.08%) 
Paris N (%) 8 (22.22%) 9 (18.75%) 
Ulm N (%) 9 (25%) 15 (31.25%) 
CAG [Mean (SD) Range]   43.31 (2.61) 39 - 54 
Disease Burden Score [Mean (SD) 
Range] 
  366.59 (85.66) 226.41 - 559.18 
Total Functional Capacity [Mean (SD) 
Range] 
12.97 (0.17) 12 - 13 12.02 (0.93) 9 - 13 
Total Motor Score [Mean (SD) Range] 1.44 (1.89) 0 - 7 18.58 (9.19) 6 - 45 
Disease burden score [77] calculated as [age x (cag-35.5)]. SD = standard deviation. ISCED = International Standard 
Classification of Education. CAG = tri-nucleotide repeat length. 
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Table 2. Baseline comparison of diffusion metrics in white matter regions between early HD patient and controls 
 
Brain region Fractional Anisotropy P Axial Diffusivity P Radial Diffusivity P 
Cingulum (cingulate gyrus) - L -0.033 [-0.055, -0.012] 0.002 0.019 [-0.009, 0.047] 0.188 0.055 [0.025, 0.085] <0.001 
Cingulum (cingulate gyrus) - R -0.031 [-0.050, -0.011] 0.002* 0.000 [-0.026, 0.027] 0.975 0.042 [0.015, 0.069] 0.002* 
Corona radiata - Anterior - L -0.007 [-0.019, 0.005] 0.264 0.037 [0.019, 0.055] <0.001* 0.025 [0.007, 0.044] 0.006* 
Corona radiata - Anterior - R -0.009 [-0.024, 0.006] 0.245 0.039 [0.017, 0.060] <0.001* 0.027 [0.004, 0.050] 0.023* 
Corona radiata - Posterior - L -0.006 [-0.021, 0.008] 0.383 0.037 [0.018, 0.056] <0.001* 0.024 [0.007, 0.042] 0.007* 
Corona radiata - Posterior - R -0.008 [-0.023, 0.006] 0.273 0.038 [0.016, 0.061] 0.001* 0.031 [0.011, 0.050] 0.002* 
Corona radiata - Superior - L -0.006 [-0.019, 0.007] 0.349 0.040 [0.022, 0.059] <0.001* 0.024 [0.010, 0.038] 0.001* 
Corona radiata - Superior - R -0.006 [-0.020, 0.007] 0.364 0.036 [0.015, 0.056] 0.001* 0.021 [0.007, 0.035] 0.003* 
Corpus callosum - Body -0.023 [-0.036, -0.010] <0.001* 0.060 [0.038, 0.081] <0.001* 0.054 [0.032, 0.076] <0.001* 
Corpus callosum - Genu -0.026 [-0.041, -0.011] 0.001* 0.046 [0.021, 0.070] <0.001* 0.051 [0.022, 0.080] 0.001* 
Corpus callosum - Splenium -0.023 [-0.034, -0.011] <0.001* 0.082 [0.050, 0.114] <0.001* 0.058 [0.032, 0.084] <0.001* 
External capsule - L -0.018 [-0.028, -0.008] <0.001* 0.043 [0.027, 0.058] <0.001* 0.046 [0.028, 0.064] <0.001* 
External capsule - R -0.011 [-0.023 , 0.000 ] 0.052 0.057 [0.038, 0.075] <0.001* 0.045 [0.024, 0.066] <0.001* 
Internal capsule - Anterior limb - L 0.001 [-0.012, 0.014] 0.927 0.064 (0.046, 0.083) <0.001* 0.031 [0.014, 0.047] <0.001* 
Internal capsule - Anterior limb - R 0.000 [-0.012, 0.013] 0.948 0.060 [0.040, 0.080] <0.001* 0.039 [0.021, 0.057] <0.001* 
Internal capsule - Retrolenticular - L 0.003 [-0.011, 0.017] 0.666 0.055 [0.034, 0.077] <0.001* 0.018 [-0.001, 0.037] 0.059 
Internal capsule - Retrolenticular - R -0.000 [-0.014, 0.014] 0.981 0.047 [0.028, 0.067] <0.001* 0.020 [0.002, 0.037] 0.025* 
Pontine crossing tract -0.023 [-0.041, -0.005] 0.012* 0.019 [-0.012, 0.051] 0.235 0.033 [0.006, 0.060] 0.016* 
Posterior thalamic radiation - L -0.000 [-0.015, 0.015] 0.983 0.032 [0.004, 0.059] 0.023* 0.016 [-0.007, 0.039] 0.176 
Posterior thalamic radiation - R -0.008 [-0.025, 0.009] 0.366 0.035 [0.002, 0.067] 0.035* 0.025 [-0.005, 0.055] 0.106 
Sagittal stratum - L -0.023 [-0.036, -0.010] 0.001* 0.059 [0.028, 0.090] <0.001* 0.062 [0.037, 0.088] <0.001* 
Sagittal stratum - R -0.016 [-0.031, -0.002] 0.029 0.034 [0.002, 0.067] 0.039* 0.035 [0.008, 0.061] 0.010 
Superior longitudinal fasciculus – L -0.011 [-0.024, 0.001] 0.083 0.025 [0.011, 0.040] 0.001* 0.027 [0.010, 0.044] 0.002* 
Superior longitudinal fasciculus - R -0.014 [-0.026, -0.001] 0.032 0.031 [0.017, 0.045] <0.001* 0.031 [0.014, 0.049] <0.001* 
Values are in the form of adjusted group difference estimates, with 95% confidence intervals presented in brackets.  
*Denotes statistically significant group differences after FDR correction 
L = Left, R = Right 
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Table 3. Early HD and control longitudinal rate of change comparison 
Brain Region  Fractional Anisotropy P Axial Diffusivity P Radial Diffusivity P 
Cingulum (cingulate gyrus) - L 0.002 [-0.006, 0.010] 0.627 -0.002 [-0.013, 0.008] 0.693 -0.004 [0.015, 0.007] 0.489 
Cingulum (cingulate gyrus) - R -0.004 [-0.010, 0.002] 0.216 0.003 [-0.008, 0.015] 0.578 0.006 [-0.003, 0.017] 0.208 
Corona radiata - Anterior - L -0.005 [-0.012, 0.000] 0.077 0.017 [0.005, 0.028] 0.003* 0.015 [0.004, 0.026] 0.006* 
Corona radiata - Anterior - R -0.007 [-0.014, -0.000] 0.035 0.007 [-0.004, 0.018] 0.216 0.011 [0.000, 0.021] 0.042 
Corona radiata - Posterior - L 0.001 [-0.004, 0.008] 0.568 0.002 [-0.007, 0.012] 0.597 0.000 [-0.008, 0.010] 0.856 
Corona radiata - Posterior - R -0.002 [-0.007, 0.003] 0.435 0.008 [0.000, 0.015] 0.028 0.004 [-0.002, 0.011] 0.196 
Corona radiata - Superior - L -0.001 [-0.005, 0.003] 0.615 0.008 [0.001, 0.015] 0.020 0.004 [-0.001, 0.011] 0.155 
Corona radiata - Superior - R -0.002 [-0.008, 0.002] 0.302 0.009 [0.002, 0.016] 0.006* 0.005 [-0.001, 0.012] 0.111 
Corpus callosum - Body -0.012 [-0.017, -0.007] <0.001* 0.012 [0.001, 0.022] 0.020 0.020 [0.011, 0.028] <0.001* 
Corpus callosum - Genu -0.006 [-0.010, -0.002] 0.004* 0.023 [0.014, 0.033] <0.001* 0.018 [0.010, 0.026] <0.001* 
Corpus callosum - Splenium -0.000 [-0.005, 0.004] 0.879 0.004 [-0.007, 0.016] 0.441 0.001 [-0.008, 0.010] 0.808 
External capsule - L -0.004 [-0.009, 0.000] 0.092 0.006 [-0.003, 0.015] 0.193 0.007 [0.000, 0.015] 0.044 
External capsule - R -0.004 [-0.010, 0.001] 0.137 0.008 [-0.002, 0.019] 0.134 0.008 [-0.001, 0.018] 0.090 
Internal capsule - Anterior limb - L 0.003 [-0.003, 0.010] 0.288 0.011 [0.000, 0.022] 0.041 0.000 [-0.009, 0.009] 0.943 
Internal capsule - Anterior limb - R -0.004 [-0.012, 0.004] 0.365 0.026 [0.012, 0.041] <0.001* 0.016 [0.003, 0.030] 0.012 
Internal capsule - Retrolenticular - L 0.003 [-0.006, 0.013] 0.521 0.003 [-0.009, 0.016] 0.579 -0.001 [-0.014, 0.012] 0.834 
Internal capsule - Retrolenticular - R 0.001 [-0.006, 0.009] 0.695 0.001 [-0.011, 0.014] 0.821 -0.001 [-0.011, 0.008] 0.767 
Pontine crossing tract 0.018 [0.002, 0.034] 0.025 -0.002 [-0.027, 0.023] 0.875 -0.016 [-0.040, 0.007] 0.170 
Posterior thalamic radiation - L -0.005 [-0.014, 0.003] 0.254 0.011 [-0.005, 0.028] 0.186 0.011 [-0.002, 0.024] 0.099 
Posterior thalamic radiation - R 0.000 [-0.007, 0.007] 0.974 -0.001 [-0.015, 0.011] 0.807 0.000 [-0.010, 0.011] 0.924 
Sagittal stratum - L 0.003 [-0.006, 0.012] 0.539 0.021 [0.000, 0.043] 0.049 0.009 [-0.007, 0.025] 0.281 
Sagittal stratum - R -0.005 [-0.012, 0.001] 0.114 0.006 [-0.009, 0.021] 0.427 0.012 [0.001, 0.023] 0.030 
Superior longitudinal fasciculus - L -0.000 [-0.005, 0.003] 0.708 0.002 [-0.005, 0.010] 0.516 0.003 [-0.003, 0.009] 0.361 
Superior longitudinal fasciculus - R -0.002 [-0.006, 0.001] 0.270 0.004 [-0.002, 0.010] 0.214 0.002 [-0.002, 0.008] 0.287 
Values are in the form of adjusted group difference estimates, with 95% confidence intervals presented in brackets.  
*Denotes statistically significant group differences after FDR correction 
L = Left, R = Right 
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Table 4. Association between 15-month change and CAG repeat length or baseline Disease Burden 
Score  
 CAG Disease Burden  
Estimate [95% CI]† P Estimate [95% CI]† P  
Corpus callosum - Genu AD  4.07 [-4.58, 12.73] 0.35 0.08 [-0.12, 0.29] 0.41 
Corpus callosum - Genu FA -2.43 [-6.08, 1.22] 0.19 -0.07 [-0.15, 0.02] 0.11 
Corpus callosum - Genu RD 3.88 [-3.84, 11.6] 0.32 0.11 [-0.07, 0.29] 0.23 
Corona radiata - Anterior - L AD 0.92 [-10.83, 12.68] 0.88 0.01[-0.27, 0.28] 0.97 
Corona radiata - Anterior - L RD 55.60 [-475.32, 586.57] 0.83 -1.1 [-13.47, 11.27] 0.86 
Internal capsule - Anterior limb - R AD  13.70 [-0.41, 27.87] 0.06 0.37 [0.05, 0.69] 0.03 
Corona radiata - Superior-R AD  5.42 [0.06, 10.79] 0.05 0.14 [0.01, 0.26] 0.03 
Corpus callosum - Body FA  -4.16 [-8.07, -0.25] 0.04 -0.10 [-0.19, -0.01] 0.04 
Corpus callosum - Body RD 8.70 [2.02, 15.39] 0.01 0.23 [0.07, 0.38] <0.01* 
All analyses adjusted for age, sex and study site.  
† x 10-6  
* Statistically significant after FDR correction 
FA = Fractional anisotropy 
AD = Axial diffusivity 
RD = Radial diffusivity 
L = Left, R = Right 
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Figure legends 
Figure 1. 
Overview of the unbiased longitudinal registration methods. (A) Within-subject registration performed on tensor 
images using an initial affine and subsequent non-linear step in DTI-TK to warp images from each visit to a within-
subject ‘mid-space’. A within-subject average template was then generated. (B) These within-subject average images 
were registered together, again using DTI-TK, to define a longitudinal between-subject space. The initial input images 
were then warped to this between-subject space and averaged to form a longitudinal group template, specific to the 
study. (C) Using NiftyReg to calculate affine and non-linear registrations, the FA image from the ICBM-DTI-81 atlas 
was then warped to match the group template. The parameters of this registration were then applied to ICBM-DTI-81 
labels. (D) Finally, subject and visit specific metrics for each ROI were calculated. 
Figure 2.  
The figure depicts the regions-of-interest (ROIs) that showed significant differences in rates of change in DTI metrics 
over 15 months, when comparing early HD patients and controls. The body (red) and genu (green) of the corpus 
callosum, along with the left anterior corona radiata (yellow) and right superior corona radiata (magenta) and 
anterior limb of internal capsule (blue) are shown. A) Coronal, B) sagittal and C) axial 2D slices, along with D) 3D 
representation are displayed in order to illustrate the spatial relatedness of the five significant regions. 
Figure 3. 
Longitudinal trajectories of DTI metrics for early HD patients and controls for all significant metric-ROI combinations. 
The fitted values depicted were calculated for hypothetical participants age 50, with a 50/50 male-female split and a 
25% contribution from each site. Points are plotted at each assessment (baseline, 6 months, 15 months), with the 
dashed line representing early HD patients and the whole line representing controls. 
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Figures 
Figure 1. 
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Figure 3. 
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Supplementary Information 
 
Supplementary Methods 
Diffusion Tensor Imaging: Gradient Directions  
We acquired DTI data in 42 gradient directions from three sites (London, Paris, Leiden) and in 47 gradient directions 
from one site (Ulm). The number of gradient directions is an important component within a DTI sequence and can 
impact the accuracy of tensor estimation and subsequent DTI metric values. However, while studies have shown that 
an increase in number of gradient directions from 6 to 12, for example, can have a substantial effect on the precision 
of DTI measurements [78] the optimal number of gradient directions has an upper limit. Jones has shown that 20 
directions are required to achieve a robust estimate of anisotropy, while 30 directions are required for robust 
estimation of the tensor orientation and MD [79]. Similarly, Poonawalla et al. have shown that increasing the number 
of gradient directions has progressively less impact on diffusion metrics, with a plateau around 30-35 gradient 
directions [80]. Finally, it should be noted that error bias is related to SNR and remains unaffected by an increase in 
the number of gradient directions [81]. A recent multisite study in premanifest HD patients investigated the impact of 
increasing number of gradient directions in a dataset of premanifest Huntington’s disease patients and controls on 
the quality of the FA maps. This study showed that there was still high agreement between FA maps that had 
included all gradient directions compared to those where up to 46 gradient directions were excluded [82]. 
Diffusion Tensor Imaging: Motion  
Motion can be a major confounding factor in diffusion MRI. We, therefore, adopted a number of measures to combat 
the effects of motion on the quality of our DTI data. Firstly, during the scanning session, all participants had padding 
surrounding the head to reduce motion and were asked to keep very still while the DTI sequence was performed. We 
are aware, that participants with HD are more prone to movement within the scanner given the nature of their 
condition and therefore, may induce more motion artefacts than a healthy control group.  It is important to note that, 
however, that, all but one of the patients were Stage 1-HD, having only recently received clinical motor diagnosis of 
HD and so their movement within the scanner would be potentially lower than other HD patients in more advanced 
stages of the disease. Nevertheless, it was likely that HD patient data would show more effect of motion and so we 
implemented a strict visual quality control procedure. For each participant, we inspected every slice of all gradient 
and non-gradient volumes for each timepoint. This is a very effective way of identifying motion-related artefacts, 
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while also ensuring even sampling (which is not the case with automated quality control software). Following tensor-
fit and at every subsequent stage of pre-processing, the data were visually inspected for possible effects of motion. 
Most importantly, prior to any processing, we corrected the data for any motion-induced currents using eddy-current 
correction in FSL; the b-vectors (gradient directions) were then updated accordingly and this updated motion-related 
information used in subsequent processing steps. A recent study investigated the effects of movement on the quality 
of DTI data in the HD population, using an outlier detection algorithm to compare the index DWI direction against a 
weighted average computed from all other directions of the same subject [22]. This study showed that no significant 
differences were observed when independently comparing groups of patients, both with and without removal of DWI 
volumes that contained artefacts and that further still, hypothesized white matter differences based on the existing 
literature were still detectable. 
Correction for white matter atrophy 
We chose not to control for white matter atrophy, because we believe that the disease processes underlying 
macroscopic white matter volume changes are strongly related to those which result in white matter microstructural 
changes. Consequently, co-varying for white matter atrophy would confound the disease effect under investigation. 
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SI Table 1. Comparison of excluded and included HD patient demographics 
Baseline characteristics Excluded HD patients Included HD patients 
N 13  48  
Age (Years) [Mean (SD) Range] 47.56 (15.54) 23.49 - 65.94 48.94 (9.38) 26.77 - 67.29 
Sex (Female/Male N (%)) 8/5 (61.5%) / (38.5%) 29 / 19 (60.4%) / (39.6%) 
Education Level (ISCED) [Mean (SD) Range] 3.46 (1.27)  2-6 3.42 (1.27) 2 - 6 
Centre      
Leiden N (%)  6 (46.15%) 11 (22.92%) 
London N (%)  3 (23.08%) 13 (27.08%) 
Paris N (%) 4 (30.77%) 9 (18.75%) 
Ulm N (%) 0 (0%) 15 (31.25%) 
CAG [Mean (SD) Range] 45.46 (4.54) 39 - 53 43.31 (2.61) 39 - 54 
Disease Burden Score [Mean (SD) Range] 412.87 (75.46) 230.77 -511.07 366.59 (85.66) 226.41 - 559.18 
Total Functional Capacity [Mean (SD) Range] 10.69 (2.36) 5-13 12.02 (0.93) 9 - 13 
Total Motor Score [Mean (SD) Range] 25.54 6-58 18.58 (9.19) 6 - 45 
Disease burden score calculated as [age x (cag-35.5)] 
SD = standard deviation 
ISCED = International Standard Classification of Education 
CAG = tri-nucleotide repeat length. 
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SI Table 2. Longitudinal site specific interaction 
Region and DTI metric Site P value for interaction 
  Leiden London Paris Ulm  
 
Baseline between-group differences  
Cingulum Cingulate - L - FA -0.042 [-0.084 , -0.001]* 0.011 [-0.051 , 0.072]  0.013 [-0.046 , 0.072] 0.013 [-0.053 , 0.079]  
Cingulum Cingulate - L - RD  0.097 [0.04 , 0.153]* -0.062 [-0.147 , 0.023] -0.059 [-0.14 , 0.022] -0.057 [-0.148 , 0.035]  
Post thalamic radiation - L - RD  -0.016 [-0.06 , 0.029] 0.04 [-0.026 , 0.106]  0.037 [-0.026 , 0.1] 0.058 [-0.012 , 0.129]  
Sagittal Stratum - R - RD 0.054 [0.003 , 0.105]*  -0.01 [-0.086 , 0.065] -0.026 [-0.098 , 0.047] -0.048 [-0.129 , 0.033]  
 
Longitudinal between-group difference (15 month change)  
Cingulum Cingulate Left FA  0.021 [0.007 , 0.035]* -0.014 [-0.028 , 0.001] -0.009 [-0.022 , 0.004] 0.001 [-0.015 , 0.018] 0.001* 
Cingulum Cingulate Left RD  -0.032 [-0.052 , -0.012]* 0.018 [-0.003 , 0.04] 0.012 [-0.007 , 0.031] -0.001 [-0.025 , 0.022] 0.001* 
Post thalamic radiation Left RD  0.046 [0.023 , 0.069]* -0.014 [-0.04 , 0.011] 0.006 [-0.017 , 0.029] -0.005 [-0.034 , 0.023] 0.003* 
Sagittal Stratum Right RD  0.009 [-0.011 , 0.029] -0.02 [-0.041 , 0.002] 0.028 [0.008 , 0.047]* 0.03 [0.006 , 0.054]* 0.006* 
Site specific results from the primary analysis for 4 metrics suggesting site interactions were present after adjustment for multiple comparison based on 24 ROI for each 
diffusion metric.  
Values are in the form of adjusted group difference estimates, with 95% confidence intervals presented in brackets.  
* Denotes p-value > 0.05 uncorrected. 
FA = Fractional anisotropy 
RD = Radial diffusivity 
L = Left, R = Right 
 
 
